CareDx (CDNA) Q2 2025: Adjusted Revenue Rises 14% as Protocol Adoption and AI Diagnostics Drive Growth
CareDx posted a strong quarter with adjusted revenue up double-digits and clear momentum in kidney surveillance protocols, but looming reimbursement policy changes and a CFO transition introduce new variables for the back half of 2025. The company’s operational improvements and clinical evidence pipeline are translating into volume and margin gains, yet reimbursement headwinds and bundled payment scenarios could reshape the growth trajectory. Investors face a classic execution versus policy risk tradeoff as CareDx enters a pivotal period for both clinical adoption and payer negotiations.
Summary
- Protocol Expansion Drives Volume: Kidney surveillance testing protocols exceeded 60 nationally, fueling broad-based test volume growth.
- AI Diagnostics and RCM Execution: Launch of AlloSure Plus and robust revenue cycle management improvements underpin margin expansion.
- Reimbursement Policy Uncertainty: Draft LCD scenarios signal up to $30 million headwind, leaving future margin and revenue visibility contingent on final policy.
Performance Analysis
CareDx delivered adjusted revenue growth of 14% year-over-year, propelled by a 13% increase in total testing volumes and continued expansion of kidney surveillance protocols. The company’s eighth consecutive quarter of sequential testing volume growth underscores sustained demand across kidney, heart, and lung segments, with kidney testing up nearly 20% year-over-year as protocol adoption accelerated. Patient and digital solutions, which include transplant pharmacy and remote monitoring, grew 19%, while lab products revenue rose 12%, both contributing to the top-line momentum.
Gross margins improved meaningfully across all key segments, with adjusted non-GAAP gross margin reaching 70.4% and testing services margin expanding 120 basis points to 77.6%. Lab product gross margin jumped 17 points to 63.9%, aided by price increases and a favorable shift toward higher-margin NGS kits. Operating leverage was evident as operating expenses grew just 3%, well below revenue growth, supporting a swing to $9.1 million in adjusted EBITDA from a loss last year. Cash generation was solid, with $10 million from operations and a $50 million share repurchase, leaving the company with $186 million in cash and no debt.
- Testing Volume Momentum: Sequential and year-over-year testing growth was broad-based, with kidney protocols as the primary engine.
- Margin Expansion: Revenue cycle management (RCM, insurance claim and billing optimization) drove higher payment per test and lower claim rejection rates.
- Balanced Segment Growth: Patient and digital solutions outpaced core testing, while product mix shifts in lab products improved profitability.
CareDx’s operational discipline is translating into financial results, but headline revenue was impacted by a one-time $3.8 million write-off on prior period tests, a dynamic management expects not to recur. The company reaffirmed full-year revenue and EBITDA guidance, reflecting confidence in underlying demand and expense control.
Executive Commentary
"We made good progress against our growth drivers and financial KPIs in the second quarter... It was our eighth consecutive quarter of sequential testing volume growth, with growth across all three organs, heart, kidney, and lung. Our growth strategy is working."
John Hanna, President and CEO
"Adjusted to exclude impacts associated with tests performed in prior periods, our non-GAAP gross margin improved 340 basis points to 70.4%... The improvement was primarily driven by strong volume growth and continued efficiencies in our lab operations."
Abhishek Jain, Chief Financial Officer
Strategic Positioning
1. Kidney Surveillance Protocol Adoption
Kidney protocol expansion has become the company’s core volume and revenue driver, with over 60 protocols now live nationally. This shift from “for-cause” to surveillance testing reflects successful advocacy and market education efforts, enabling nearly 20% year-over-year kidney testing growth. The company’s ability to turn protocols “back on” after prior policy uncertainty has been a material catalyst for both clinical adoption and top-line growth.
2. AI-Driven Diagnostics and Clinical Evidence
The launch of AlloSure Plus, an AI-powered personalized rejection risk score, marks a strategic push into value-based, precision diagnostics. Supported by large-scale, multi-center data presented at the World Transplant Congress, AlloSure Plus and related studies are building a robust evidence base to support payer negotiations and clinical adoption. This evidence generation is a direct lever for future reimbursement and protocol inclusion.
3. Revenue Cycle and Digital Infrastructure
Significant RCM improvements—such as a 60% reduction in claim submission time and an 800 basis point drop in claim rejection— are driving higher ASP (average selling price) per test and accelerating cash collections. The rollout of Epic, the leading electronic health record (EHR) platform, is on track to cover 10% of volume by year-end and aims for 50% adherence next year, streamlining ordering and results delivery for providers and reinforcing stickiness.
4. Policy and Reimbursement Navigation
The draft Local Coverage Determination (LCD) for molecular transplant testing introduces major reimbursement risk, with two modeled scenarios ranging from a $15 million to $30 million annual headwind depending on frequency limits and bundled payment adoption. Management’s public advocacy is focused on preserving provider flexibility, multimodal testing reimbursement, and opposing restrictive bundling, all of which will shape the company’s long-term margin and revenue profile.
5. Leadership Transition
The CFO transition from Abhishek Jain to Nathan Smith (a Myriad Genetics veteran) adds uncertainty but also brings deep diagnostics industry experience. Jain’s operational discipline underpinned the return to profitability, and the transition will be closely watched for continuity in financial execution and capital allocation.
Key Considerations
CareDx’s quarter was defined by strong operational execution and clinical adoption, but the reimbursement landscape and leadership transition introduce new strategic variables for investors to monitor.
Key Considerations:
- Protocol-Driven Growth Sustainability: The durability of kidney and heart protocol adoption will hinge on ongoing payer and policy support.
- AI Diagnostic Differentiation: AlloSure Plus and related AI tools could accelerate clinical adoption if payer acceptance and Epic integration scale as planned.
- Reimbursement Policy Overhang: Final LCD language, especially around bundling and frequency, will directly impact revenue and margin structure.
- Operational Leverage: Continued RCM and digital integration gains are necessary to offset potential reimbursement pressure and maintain EBITDA targets.
- Leadership Continuity: The CFO transition timing is critical, given the need for ongoing cost discipline and policy navigation.
Risks
The most material risk is the pending LCD policy, which could introduce up to a $30 million annual revenue headwind if bundling and test frequency limits are finalized as proposed. Additional risks include potential delays in Epic EHR integration, competitive encroachment in AI diagnostics, and possible disruption or inertia during the CFO leadership transition. Policy-driven volume impacts and ASP compression remain the primary investor concern for the next several quarters.
Forward Outlook
For Q3, CareDx guided to:
- Testing volume growth of 2–3% sequentially
- Continued margin expansion from operational improvements
For full-year 2025, management reaffirmed and narrowed guidance:
- Revenue of $367–$373 million
- Adjusted EBITDA of $29–$33 million
- Full-year ASP of $1,360 per test (excludes policy changes)
Management emphasized that guidance assumes no change to current medical coverage and that any finalized LCD impact will be modeled and communicated once policy is clear.
- Test volume growth is expected to remain in the mid-teens percent YoY
- Patient and digital solutions projected to grow in the low 20% range
Takeaways
CareDx’s Q2 results highlight the power of protocol-driven growth and operational execution, but the reimbursement policy environment remains a swing factor for the medium term.
- Protocol Adoption Is the Growth Engine: Kidney surveillance expansion and AI diagnostics are translating to sustained volume and margin gains, but their future depends on reimbursement clarity.
- Operational Leverage Is Evident: Revenue cycle wins, digital integration, and cost control have restored profitability and positioned the company to weather policy shifts—assuming execution continues post-CFO transition.
- Policy Risk Is the Elephant in the Room: Final LCD language will determine whether current growth is sustainable or reset, making payer engagement and advocacy outcomes the top watchpoint for investors.
Conclusion
CareDx delivered on its operational and clinical adoption playbook in Q2, but the next chapter will be written by policy outcomes and the company’s ability to maintain commercial momentum through a leadership change. The balance of execution upside and reimbursement risk defines the investment debate heading into the second half of 2025.
Industry Read-Through
The CareDx quarter underscores several industry-wide themes for diagnostics and transplant monitoring: First, protocol-driven adoption and AI-powered risk stratification are becoming table stakes for clinical differentiation and payer negotiations. Second, reimbursement policy volatility remains a structural risk, with bundling and test frequency limits likely to impact the broader molecular diagnostics landscape. Finally, revenue cycle and digital integration are emerging as critical sources of margin expansion and competitive advantage, especially as payers demand more evidence and cost control. Companies across diagnostics and precision medicine should expect similar policy headwinds and must invest in operational excellence to sustain growth amidst reimbursement uncertainty.